Education
About Us
Working with TipRanks
Follow Us
Tectonic Therapeutic (TECX)
NASDAQ:TECX
TECX Stock Chart & Stats
$19.56
-$0.66(-1.42%)
At close: 4:00 PM EST
$19.56
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$13.70 - $61.07
Previous CloseN/A
Volume30.18K
Average Volume (3M)352.00K
Market Cap
$366.09M
Enterprise ValueN/A
Total Cash (Recent Filing)$268.44M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 19, 2026EPS Estimate
-1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding18,716,280
10 Day Avg. Volume392,664
30 Day Avg. Volume351,998
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)2.78
Price to Sales (P/S)0.00
P/FCF Ratio-6.62
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$86.25Price Target Upside340.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMerck's decision to progress to a Phase 3 study suggests strong data from its Phase 2 CADENCE trial, which could have a positive influence on Tectonic's TX45.
Financial StabilityTectonic ends Q3 with $268.4M on the balance sheet, which is expected to fund operations into the fourth quarter of 2028.
Market PotentialRecent positive Phase 1b PH-HFrEF data potentially opens up TX45's total addressable market.
Bears Say
Investor SentimentShort interest is at 33.6% of float, indicating significant bearish sentiment among investors.
Potential Study FailureThe worst-case scenario for TECX would be if AZD3427 is removed from Phase II, indicating a failed study and discontinued development.
Trial ChallengesChallenges in the Re-PHIRE trial design could make it difficult to achieve its primary endpoint, influencing TECX negatively.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic’s price range in the past 12 months?
Tectonic Therapeutic lowest stock price was $13.70 and its highest was $61.07 in the past 12 months.
What is Tectonic Therapeutic’s market cap?
Tectonic Therapeutic’s market cap is $366.09M.
When is Tectonic Therapeutic’s upcoming earnings report date?
Tectonic Therapeutic’s upcoming earnings report date is Mar 19, 2026 which is in 86 days.
How were Tectonic Therapeutic’s earnings last quarter?
Tectonic Therapeutic released its earnings results on Nov 06, 2025. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.056 by $0.036.
Is Tectonic Therapeutic overvalued?
According to Wall Street analysts Tectonic Therapeutic’s price is currently Undervalued.
Does Tectonic Therapeutic pay dividends?
Tectonic Therapeutic does not currently pay dividends.
What is Tectonic Therapeutic’s EPS estimate?
Tectonic Therapeutic’s EPS estimate is -1.13.
How many shares outstanding does Tectonic Therapeutic have?
Tectonic Therapeutic has 18,716,280 shares outstanding.
What happened to Tectonic Therapeutic’s price movement after its last earnings report?
Tectonic Therapeutic reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.056. Following the earnings report the stock price went up 1.738%.
Which hedge fund is a major shareholder of Tectonic Therapeutic?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.25 (340.95% Upside)
$86.25 (340.95% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 334.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.60%
12-Months-Change
Fundamentals
Return on Equity
-32.21%
Trailing 12-Months
Asset Growth
64.18%
Trailing 12-Months
Company Description
Tectonic Therapeutic
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$86.25
▲(340.95% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
38.51% Insiders
13.87% Mutual Funds
28.17% Other Institutional Investors
13.67% Public Companies and Individual Investors
Options Prices
Currently, No data available
---